growing rapidly to answer mandates and demands from government regulatory and reimbursement agencies, medical insurance providers, healthcare professionals, patient advocacy groups, and patients for improved patient outcomes and lower healthcare costs. Anticipated refinements and advances in these core technologies are directly applicable to several additional patient diagnostic and monitoring markets, including the consumer/diabetic self monitoring market valued at nearly $12B annually.

MAI’s business model is to license our innovative IP for utilization in a variety of medical testing and automated monitoring devices. The licensing model provides the opportunity for very rapid growth from multiple global licenses that include ongoing and growing revenue from royalties based on the sales of devices, and disposables that create renewable revenue. Licensing allows MAI to generate profits at much lower cost without traditional increases in infrastructure and overhead expense common in the medical device industry. These advantages are “Flagged” in our EquityNet Business Plan and illustrate the advantages of applying our business model to very large and rapidly growing markets.

MAI is a for profit Wyoming Corporation with a primary focus on generating automated prototypes using technological concepts that have been fundamentally proven to initiate marketing of our early stage IP.